Serological Surveillance of COVID-19 Hospitalized Patients in Réunion Island (France) Revealed that Specific Immunoglobulin G Are Rapidly Vanishing in Severe Cases.

COVID-19 Western blot disease severity enzyme-linked immunosorbent assay immunoglobulin G intensive care unit serological analyses

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
27 Nov 2020
Historique:
received: 30 09 2020
revised: 06 11 2020
accepted: 10 11 2020
entrez: 2 12 2020
pubmed: 3 12 2020
medline: 3 12 2020
Statut: epublish

Résumé

Humoral immunity is critically important to control COVID-19. Long-term antibody responses remain to be fully characterized in hospitalized patients who have a high risk of death. We compared specific Immunoglobulin responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) between two groups, intensive care unit (ICU) and non-ICU hospitalized patients over several weeks. Plasma specific IgG, IgM, and IgA levels were assessed using a commercial ELISA and compared to an in-house cell-based ELISA. Among the patients analyzed (mean (SD) of age, 64.4 (15.9) years, 19.2% female), 12 (46.2%) were hospitalized in ICU. IgG levels increased in non-ICU cases from the second to the eighth week after symptom onset. By contrast, IgG response was blunted in ICU patients over the same period. ICU patients with hematological malignancies had very weak or even undetectable IgG levels. While both groups had comparable levels of specific IgM antibodies, we found much lower levels of specific IgA in ICU versus non-ICU patients. In conclusion, COVID-19 ICU patients may be at risk of reinfection as their specific IgG response is declining in a matter of weeks. Antibody neutralizing assays and studies on specific cellular immunity will have to be performed.

Identifiants

pubmed: 33260801
pii: jcm9123847
doi: 10.3390/jcm9123847
pmc: PMC7761058
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Regional Council of La Réunion and State of France
ID : CPER-FEDER COVI-RUN Program

Références

Euro Surveill. 2020 Feb;25(6):
pubmed: 32070465
Blood. 2020 Nov 26;136(22):2588-2591
pubmed: 33001206
PLoS Negl Trop Dis. 2020 Aug 3;14(8):e0008476
pubmed: 32745101
Clin Infect Dis. 2020 Jun 29;:
pubmed: 32594121
Euro Surveill. 2020 Jul;25(28):
pubmed: 32700670
J Clin Med. 2020 Jun 16;9(6):
pubmed: 32560227
Lancet Infect Dis. 2020 Apr;20(4):398-400
pubmed: 32113510
Nat Commun. 2020 Oct 2;11(1):4968
pubmed: 33009413
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
J Gen Intern Med. 2020 Oct;35(10):3063-3066
pubmed: 32737790
Cell Rep Med. 2020 Oct 20;1(7):100126
pubmed: 33015650
Lancet Infect Dis. 2020 May;20(5):565-574
pubmed: 32213337
Cell Death Differ. 2020 May;27(5):1451-1454
pubmed: 32205856
J Clin Med. 2020 Oct 01;9(10):
pubmed: 33019628
Euro Surveill. 2020 Feb;25(5):
pubmed: 32046819
Clin Transl Immunology. 2020 May 06;9(5):e01136
pubmed: 32382418
J Infect Dis. 2020 May 11;221(11):1762-1769
pubmed: 32227123
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Nat Microbiol. 2020 Dec;5(12):1598-1607
pubmed: 33106674
Cytometry A. 2020 Aug;97(8):772-776
pubmed: 32542842
Clin Infect Dis. 2020 Aug 25;:
pubmed: 32840608
N Engl J Med. 2007 Sep 13;357(11):1162-3
pubmed: 17855683
Anesthesiology. 2020 Jun;132(6):1346-1361
pubmed: 32195698
mBio. 2020 Oct 16;11(5):
pubmed: 33067385
Emerg Microbes Infect. 2020 Dec;9(1):1664-1670
pubmed: 32618497
J Clin Virol. 2006 Feb;35(2):179-84
pubmed: 16112612
Euro Surveill. 2020 Mar;25(11):
pubmed: 32209163
Aging Dis. 2020 May 9;11(3):642-648
pubmed: 32489708

Auteurs

Anthony Dobi (A)

Unité de Recherche en Pharmaco-Immunologie (UR-EPI), Université et CHU de La Réunion, 97400 Saint-Denis, France.

Anne-Laure Sandenon Seteyen (AL)

Unité de Recherche en Pharmaco-Immunologie (UR-EPI), Université et CHU de La Réunion, 97400 Saint-Denis, France.

Mahary Lalarizo Rakoto (M)

Unité de Recherche en Pharmaco-Immunologie (UR-EPI), Université et CHU de La Réunion, 97400 Saint-Denis, France.
Faculté de Médecine, Campus universitaire Ambohitsaina, BP375, 101 Antananarivo, Madagascar.

Grégorie Lebeau (G)

Unité de Recherche en Pharmaco-Immunologie (UR-EPI), Université et CHU de La Réunion, 97400 Saint-Denis, France.

Damien Vagner (D)

UMR PIMIT 'Processus Infectieux en Milieu Insulaire Tropical' CNRS 9192, INSERM1187, IRD 249, Université de La Réunion, 97400 Saint-Denis, France.

Étienne Frumence (É)

Unité de Recherche en Pharmaco-Immunologie (UR-EPI), Université et CHU de La Réunion, 97400 Saint-Denis, France.

Claude Giry (C)

Unité de Recherche en Pharmaco-Immunologie (UR-EPI), Université et CHU de La Réunion, 97400 Saint-Denis, France.
CNR Associé Arbovirus, Laboratoire de Microbiologie, Pôle de Biologie, CHU de La Réunion, 97440 Saint-Denis, France.

Axelle Septembre-Malaterre (A)

Unité de Recherche en Pharmaco-Immunologie (UR-EPI), Université et CHU de La Réunion, 97400 Saint-Denis, France.

Loïc Raffray (L)

Unité de Recherche en Pharmaco-Immunologie (UR-EPI), Université et CHU de La Réunion, 97400 Saint-Denis, France.
UMR PIMIT 'Processus Infectieux en Milieu Insulaire Tropical' CNRS 9192, INSERM1187, IRD 249, Université de La Réunion, 97400 Saint-Denis, France.
Service de Médecine Interne, CHU de La Réunion, 97400 Saint-Denis, France.

Philippe Gasque (P)

Unité de Recherche en Pharmaco-Immunologie (UR-EPI), Université et CHU de La Réunion, 97400 Saint-Denis, France.
Laboratoire d'Immunologie Clinique et Expérimentale de la ZOI (LICE-OI), Pôle de Biologie, CHU de La Réunion, 97400 Saint-Denis, France.

Classifications MeSH